Palo Santo

Palo Santo is a Chicago-based life sciences venture firm focused on startups developing psychedelic therapeutics for mental health conditions. The category is unusual within healthcare venture: it combines biopharma development risk with regulatory ambiguity, evolving clinical evidence, and shifting public attitudes. Operating as a category-specialist gives Palo Santo positioning that generalist biotech investors cannot easily replicate, particularly around target indications such as treatment-resistant depression, PTSD, addiction, and end-of-life anxiety. Investment activity sits within pharma therapeutics and mental and behavioral health. Limited public information is available on a detailed partner roster and portfolio composition in conventional venture format, but the firm’s category mandate is distinctive and clear.

Palo Santo participates at Seed and Series A with check sizes of $1M to $5M, sizing that allows the fund to lead or co-lead early institutional rounds in psychedelic therapeutics companies. Geographic focus is United States-anchored, where FDA pathway evolution, scheduled-substance regulation, and clinical trial design largely set global standards for the category. The Chicago base places the firm outside the typical coastal biotech clusters but does not appear to constrain deal flow.

For founders, Palo Santo is best engaged as a specialist investor that understands the unique combination of biopharma rigor and category-specific regulatory navigation that psychedelic therapeutics require. Diligence will weigh clinical mechanism, trial design, and regulatory strategy together, and the firm’s value extends beyond capital into category networks and policy fluency. Teams developing non-psychedelic mental health therapeutics, digital mental health products, or recreational psychedelic businesses are not the right fit; the mandate is specifically about regulated medical use.